Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Set To File NDA For Antipsychotic Bifeprunox In 2006

This article was originally published in The Pink Sheet Daily

Executive Summary

Wyeth has partnered with Solvay to structure a development plan for the atypical antipsychotic.

You may also be interested in...



Wyeth Says Bifeprunox Side Effect Profile Is Benefit Over Atypical Antipsychotics

NDA submission buoyed by four Phase III studies, including two involving active comparators.

Wyeth Says Bifeprunox Side Effect Profile Is Benefit Over Atypical Antipsychotics

NDA submission buoyed by four Phase III studies, including two involving active comparators.

Antipsychotic Drug Stabilization Period For Long-Term Studies Can Be Short, Vanda Pharma Says

Patient response periods in past studies have been as short as one month, the antipsychotic drug developer maintains in briefing materials for Oct. 25 meeting of psychopharmacologic advisory committee.

Related Content

Topics

UsernamePublicRestriction

Register

PS061144

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel